Rigosertib is a small molecule in preclinical development that, due to its characteristics as a dual PLK1 and PI3K inhibitor, is particularly effective in counteracting the advance of different types of tumors. In this work, we evaluated the efficacy of Rigosertib and the expression of p53 in five different human tumor cell lines in vitro, A549 (lung adenocarcinoma), MCF-7 and MDA-MB231 (breast cancer cells), RPMI 8226 (multiple myeloma), and U87-MG (glioblastoma). We demonstrated that in all cell lines, the effect was dose- and time-dependent, but A549 cells were the most sensible to the treatment while higher concentrations were required for the most resistant cell line U87-MG. Moreover, the highest and lowest p53 levels have been observed, respectively, in A459 and U87-MG cells. The alterations in the cell cycle and in cell-cycle-related proteins were observed in A549 at lower concentrations than U87-MG. In conclusion, with this article we have demonstrated that Rigosertib has different efficacy depending on the cell line considered and that it could be a potential antineoplastic agent against lung cancer in humans.

Malacrida, A., Deschamps-Wright, M., Rigolio, R., Cavaletti, G., Miloso, M. (2023). Another Brick to Confirm the Efficacy of Rigosertib as Anticancer Agent. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 24(2) [10.3390/ijms24021721].

Another Brick to Confirm the Efficacy of Rigosertib as Anticancer Agent

Malacrida A.
Primo
;
Rigolio R.;Cavaletti G.;Miloso M.
Ultimo
2023

Abstract

Rigosertib is a small molecule in preclinical development that, due to its characteristics as a dual PLK1 and PI3K inhibitor, is particularly effective in counteracting the advance of different types of tumors. In this work, we evaluated the efficacy of Rigosertib and the expression of p53 in five different human tumor cell lines in vitro, A549 (lung adenocarcinoma), MCF-7 and MDA-MB231 (breast cancer cells), RPMI 8226 (multiple myeloma), and U87-MG (glioblastoma). We demonstrated that in all cell lines, the effect was dose- and time-dependent, but A549 cells were the most sensible to the treatment while higher concentrations were required for the most resistant cell line U87-MG. Moreover, the highest and lowest p53 levels have been observed, respectively, in A459 and U87-MG cells. The alterations in the cell cycle and in cell-cycle-related proteins were observed in A549 at lower concentrations than U87-MG. In conclusion, with this article we have demonstrated that Rigosertib has different efficacy depending on the cell line considered and that it could be a potential antineoplastic agent against lung cancer in humans.
Articolo in rivista - Articolo scientifico
cell cycle; glioblastoma; lung cancer; p53; rigosertib;
English
15-gen-2023
2023
24
2
1721
open
Malacrida, A., Deschamps-Wright, M., Rigolio, R., Cavaletti, G., Miloso, M. (2023). Another Brick to Confirm the Efficacy of Rigosertib as Anticancer Agent. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 24(2) [10.3390/ijms24021721].
File in questo prodotto:
File Dimensione Formato  
Malacrida-2023-Int J Mol Sci-VoR.pdf

accesso aperto

Descrizione: Communication
Tipologia di allegato: Publisher’s Version (Version of Record, VoR)
Licenza: Creative Commons
Dimensione 3.43 MB
Formato Adobe PDF
3.43 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/404142
Citazioni
  • Scopus 2
  • ???jsp.display-item.citation.isi??? 1
Social impact